SGS Proteome: 434+ Bioactive Compounds — Clinical Synthesis
From hirudin to hirunipins: a clinical translation of the Liu 2018 proteomics landmark
Por qué esto importa para la hirudoterapia
En investigación / Prioridad de investigación
FDA 510(k)-cleared medical device. Medicinal leeches are cleared for relief of venous congestion in microsurgical procedures. The compounds described here underpin that cleared indication; additional therapeutic applications remain investigational.
The landmark discovery: from 20 to 434+ proteins
For most of the twentieth century, the known pharmacology of leech salivary gland secretion (SGS) was built around approximately 20 isolated compounds. Hirudin — characterized by Markwardt in 1957 — was the paradigm. Calin, destabilase, hyaluronidase, bdellins, and eglins completed the recognized list.
Liu et al. (2018), publishing in Annals of Medicine (PMID 29963937), applied integrated liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomics to SGS from Hirudo medicinalis and identified 434 full-length protein sequences. Of these, 44 were confirmed as bioactive through functional annotation. The Kvist et al. (2020) chromosome-level genome (PMID 32197648) subsequently provided the genomic framework.
The clinical implication is fundamental: leech therapy is not a single-molecule anticoagulant intervention. It is a coordinated, multi-target pharmacological delivery simultaneously engaging coagulation, platelet function, vascular tone, inflammation, tissue penetration, fibrinolysis, and wound defense through hundreds of molecules acting in concert.
Anticoagulant proteins: the hemostatic arsenal
Anticoagulation remains the most clinically relevant and best-characterized function of leech SGS. The proteome reveals a family of mechanistically distinct anticoagulant proteins acting at multiple points in the coagulation cascade:
Hirudin variants
The archetypal direct thrombin inhibitor. Multiple hirudin isoforms (HV1, HV2, HV3) differ in binding affinity and half-life. Hirudin binds thrombin at both the active site and the fibrinogen-recognition exosite with a dissociation constant in the femtomolar range. This compound inspired bivalirudin and desirudin, both FDA-approved, collectively generating over $600 million annually at peak commercial use.
Calin
A collagen-binding anticoagulant that blocks platelet adhesion and aggregation. Calin prevents primary hemostasis by competing with von Willebrand factor for collagen binding at the subendothelium — a mechanistically distinct antiplatelet action.
Destabilase
A multifunctional protein with both thrombolytic (fibrin-dissolving) and lysozyme-like (antimicrobial) activity. Destabilase cleaves isopeptide bonds in cross-linked fibrin — the mechanism by which mature clots are dissolved. Currently in preclinical development as a thrombolytic agent.
Anti-inflammatory proteins: beyond simple pain relief
Anti-inflammatory activity in leech SGS arises from at least four mechanistically distinct protein classes, collectively explaining the prolonged pain relief observed in osteoarthritis RCTs (3-6 months beyond a single treatment):
Eglins
Serine proteinase inhibitors (SPI) targeting elastase, cathepsin G, and chymotrypsin. Eglins suppress neutrophil-mediated tissue damage by blocking proteolytic enzymes released by activated granulocytes. The prolonged WOMAC pain reduction in OA trials is consistent with eglin-mediated reduction in synovial elastase activity.
Bdellins
Trypsin and plasmin inhibitors that modulate both inflammation and fibrinolysis. Bdellins appear to serve a regulatory function — allowing the fibrinolytic destabilase to operate at the bite wound while preventing systemic fibrinolytic activation.
Complement inhibitors
The proteome includes multiple complement system inhibitors acting at C3 and C5 convertase steps. SGS complement inhibitors may underpin the vascular protective effects reported in post-thrombotic syndrome and microsurgical flap salvage.
BDNF and neurotrophic factors
Brain-derived neurotrophic factor (BDNF) identified in leech SGS transcriptomes modulates peripheral sensitization and pain transmission at primary afferent neurons. Its presence provides a molecular basis for the analgesic effect observed clinically — distinct from the anticoagulant mechanism.
Vasodilators and penetration enhancers
Sustained local vasodilation is essential for both the feeding mechanism and the therapeutic outcomes in venous congestion. Leech SGS achieves vasodilation through at least three distinct compound classes:
Histamine-binding proteins
Leeches deploy specific histamine-binding proteins that modulate histamine vasodilatory effects with temporal precision — achieving prolonged, controlled vasodilation without the acute inflammatory response that free histamine would trigger.
Decorsin
An RGD-containing peptide that blocks GPIIb/IIIa integrin — the same target as the FDA-approved antiplatelet drug eptifibatide (Integrilin). This represents a direct leech-compound-to-drug translation pathway.
Hyaluronidase
The primary penetration enhancer in leech SGS. It degrades hyaluronan — the major glycosaminoglycan of the extracellular matrix — creating temporary channels through which other bioactive compounds diffuse into deeper tissues.
Fibrinolytic enzymes: destabilase and thrombolytic activity
Destabilase occupies a unique position as the primary fibrinolytic enzyme. Unlike mammalian plasmin (which cleaves peptide bonds), destabilase targets the isopeptide bonds in cross-linked fibrin — the bonds formed by Factor XIIIa that give mature thrombi their structural integrity. Additional fibrinolytic proteases in the proteome suggest enzymatic redundancy in clot dissolution.
Antimicrobial peptides: the wound defense network
The SGS proteome includes a dedicated antimicrobial defense network. Kumar et al. (2025), in Advanced Science (DOI 10.1002/advs.202409803), characterized hirunipins — alpha-helical cationic antimicrobial peptides with activity against multidrug-resistant bacteria and biofilm disruption capability. Earlier-characterized antimicrobials include theromacin and the antimicrobial domain of destabilase-lysozyme.
Molecular weights and concentration ranges
The therapeutic proteins span a wide range of molecular weights and act at very low concentrations:
| Protein class | MW range (kDa) | Active concentration range | Primary target |
|---|---|---|---|
| Hirudin variants | 7–8 | Femtomolar (Ki ~10⁻¹⁴ M) | Thrombin |
| Eglins | 8–12 | Nanomolar | Elastase, cathepsin G |
| Hyaluronidase | ~49 | Nanomolar | Hyaluronan (ECM) |
| Destabilase | ~12 | Nanomolar | Cross-linked fibrin |
| Hirunipins | 2–5 | Micromolar (MIC range) | Bacterial membrane |
H. medicinalis vs H. verbana: proteome differences
The Liu 2018 proteomics study focused on Hirudo medicinalis — the species regulated under FDA 510(k) clearances K040187 (Ricarimpex SAS, 2004), K132958 (Biopharm, 2014), and K140907 (Carolina Biological Supply, 2015). The closely related Hirudo verbana is predominant in European commercial markets.
Comparative proteomics reveals substantial overlap in major therapeutic protein classes but quantitative differences in specific hirudin isoform ratios. H. medicinalis is generally characterized by a higher hirudin concentration per SGS volume. Practitioners should verify that the species supplied corresponds to the FDA-cleared product specification.
Drug development pipeline: from hirudin to next-generation candidates
The leech SGS proteome has generated a traceable drug development lineage spanning more than 60 years:
Hirudin (1957) -> Bivalirudin
Hirudin's direct thrombin inhibition mechanism was reproduced in bivalirudin (Angiomax), FDA-approved for percutaneous coronary intervention and heparin-induced thrombocytopenia. Peak annual revenue exceeded $636 million before generic entry — the clearest proof-of-concept that leech SGS proteins translate to FDA-approved drugs.
Desirudin
Recombinant hirudin analog approved for deep vein thrombosis prophylaxis in patients undergoing hip replacement surgery. Demonstrates that the hirudin scaffold supports multiple distinct clinical indications.
Next-generation candidates (preclinical)
Of 434+ proteins identified, only approximately 44 have been functionally characterized. Current preclinical programs include destabilase (thrombolytic indication), hirunipins (antimicrobial resistance), and complement inhibitors (ischemia-reperfusion injury). None has entered Phase I trials as of 2025.
Clinical implications across therapeutic applications
Microsurgical flap salvage (FDA-cleared)
The convergence of anticoagulants, vasodilators, hyaluronidase, and fibrinolytics creates an optimal pharmacological environment for venous congestion management. The 78-88% salvage rates in systematic reviews reflect this multi-mechanism action.
Osteoarthritis (investigational)
The 3-6 month pain relief duration observed in Michalsen 2003 and Andereya 2006 RCTs from a single application is pharmacologically explained by the sustained anti-inflammatory activity of eglins and complement inhibitors combined with BDNF-related analgesic properties.
Referencias
- [R1]
Proteomics of Hirudo medicinalis Salivary Gland Secretion — 434 Proteins Identified
Liu et al. 434 full-length proteins by LC-MS/MS; 44 confirmed bioactive.
- [R2]
Chromosome-Level Genome Assembly of Hirudo medicinalis
Kvist et al. Genomic framework supporting the 434-protein proteome.
- [R3]
Novel Antimicrobial Peptides from Hirudo medicinalis — Hirunipins
Kumar et al. Characterization of hirunipins — new AMPs in the SGS proteome.
Recursos relacionados
Salivary Proteomics 434 Proteins
Liu 2018 proteomics study — the foundational dataset.
Más información →
Genomics & Proteomics Research
Kvist 2020 genome and proteomics overview.
Más información →
Antimicrobial Peptides — Hirunipins
Kumar et al. 2025: novel AMPs from leech SGS.
Más información →
Microsurgery Outcomes
FDA-cleared flap salvage evidence.
Más información →
Añadido a la biblioteca ASH: April 8, 2026 | Última actualización del sitio: March 18, 2026